Pay in 4 interest-free payments of $6.69 Learn more
Ships within 48 hours · Estimated delivery Aug 27 - Sep 1
Following the TRIUMPH-2 and TRIUMPH-3 results announced on 23 July 2026, Eli Lilly has confirmed it intends to file for approval in the first quarter of 2027 which places realistic UK availability in 2028 at the earliest
Lancet 391:26072618
Bottom line Retatrutide is still in clinical trials, with early data suggesting significant weight loss potential, while tirzepatide has FDA approval and proven efficacy and safety history
Let us know via [email protected].
Weight management consultations today require a thoughtful and structured approach that goes beyond basic dietary advice
Glycemic Control (GLP-1/GIP): Promotes glucose-dependent insulin secretion and suppresses inappropriate glucagon release, leading to improved HbA1c levels
US$ 26.38
US$ 29.69
US$ 21.43
US$ 27.18
US$ 25.56
